Eli Lilly (LLY.N): The company’s Taltz and Zepbound, used in combination, demonstrated superior efficacy in the first Phase 3B clinical trial in adults with psoriasis who are obese or overweight.
2026-02-18
Eli Lilly (LLY.N): The company’s Taltz and Zepbound, used in combination, demonstrated superior efficacy in the first Phase 3B clinical trial in adults with psoriasis who are obese or overweight.